LUYE PHARMA (SEHK: 02186) has announced the successful completion of its convertible bond issuance. The company confirmed that all conditions precedent under the subscription agreement have been satisfied. The issuance of bonds with a total principal amount of US$180 million was finalized on June 10, 2026.

These bonds have been listed on the Vienna Stock Exchange, effective from June 10, 2026. The initial conversion price has been set at HK$2.71 per share. This price represents a premium of approximately 24.9% over the closing price of HK$2.170 on the Hong Kong Stock Exchange on June 3, 2026, which was the trading day the subscription agreement was signed.

Furthermore, the initial conversion price also represents a premium of about 24.1% over the average closing price of HK$2.184 per share for the last five consecutive trading days up to and including June 2, 2026. The Hong Kong Stock Exchange has granted approval for the listing and trading of the shares to be issued upon conversion of these bonds.